<?xml version="1.0" encoding="UTF-8"?>
<p>Favipiravir is a drug approved for treatment of severe influenza virus infection in China. It is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. It inhibits viral polymerase activity because it can enter the cell and be recognized as a substrate by RNA polymerase when it is phosphoribosylated. It is capable of blocking the replication of several RNA virus (
 <xref rid="B108" ref-type="bibr">108</xref>). One randomized, controlled, open-label multicenter trial, showed no significant difference in disease recovery between 116 COVID-19 patients treated with favipiravir compared to 120 patients treated with arbidol, but the time of symptom improvement was shorter in favipiravir-treated individuals (not peer-reviewed) (
 <xref rid="B89" ref-type="bibr">89</xref>). Favipiravir is currently being tested in several clinic trials on COVID-19 patients.
</p>
